Kura Oncology, Inc.

9.91 USD
-0.05 (-0.50%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Kura Oncology, Inc. stock is up 9.99% since 30 days ago. The next earnings date is Feb 22, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55.56% of the previous 8 December’s closed higher than November. 100% of analysts rate it a buy.

About Kura Oncology, Inc.

Kura Oncology, Inc. develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction. tipifarnib, an orally bioavailable inhibitor of farnesyl transferase, is in Phase II clinical trials for the. treatment of solid tumors and hematologic indications.